Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Certolizumab Biosimilar Rights Revert to Xbrane from Biogen

Aug 1, 2024

On 1 August 2024, Xbrane Biopharma announced that it will regain full rights to XcimzaneTM (BIIB801) biosimilar to UCB’s Cimzia® (certolizumab pegol) for rheumatoid arthritis and psoriasis.  Xbrane and Biogen had entered into a commercialisation and licensing agreement in February 2022 under which Biogen was granted commercialisation rights to the Xbrane-developed XcimzaneTM.  That agreement has now been terminated.

According to Xbrane, BIIB801 is the only certolizumab pegol biosimilar candidate under development globally.  Xbrane reports that it has begun an out-licensing process to identify a new partner.

In October 2021, Xbrane entered into an agreement with AGC Biologics to manufacture Xcimzane™ for clinical development.